Efficacy Analysis of Semaglutide Combined with Dapagliflozin and Metformin in Obese Patients with Diabetes
Objective To explore the value of combined application of semaglutide,dapagliflozin,and metformin in obese patients with diabetes.Methods Ninety diabetic patients admitted to the First Affiliated Hospital of Henan University of Science and Technology from October 2021 to October 2023 were selected as the research sample.They were randomly divided into a study group(n=45,semaglutide+dapagliflozin+metformin)and a control group(n=45,dapagliflozin+metformin)using a random number table method.The adverse reactions,disease indicators,quality of life,and islet β-cell function were compared between the two groups.Results After treatment,there was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Before treatment,there were no statistically significant differences in disease indicators and quality of life scores between the two groups(P＞0.05).After treatment,the levels of disease indicators and quality of life scores in the study group were better than those in the control group,with statistically significant differences(P＜0.05).There was no statistically significant difference in islet β-cell function between the two groups before and after treatment(P＞0.05),but compared with before treatment,the indicators in both groups improved after treatment,with statistically significant differences(P＜0.05).Conclusion The combined application of semaglutide on the basis of dapagliflozin and metformin treatment in obese patients with diabetes can enhance efficacy,improve blood glucose and lipid levels,and weight conditions,and improve patients'quality of life.It has high safety and clinical application significance.
semaglutideobese diabetesdapagliflozinmetforminquality of life
国家科技期刊平台
NSTL
万方数据
